[1]Diab N, Patel M, O'Byrne P, et al. Narrative review of the mechanisms and treatment of cough in asthma, cough variant asthma, and non-asthmatic eosinophilic bronchitis[J]. Lung, 2022, 200(6): 707-716. DOI: 10.1007/s00408-022-00575-6.
[2]Xiong J, Qi W, Yang H, et al. Acupuncture treatment for cough-variant asthma: a meta-analysis[J]. Evid Based Complement Alternat Med, 2021, 2021: 6694936. DOI: 10.1155/2021/6694936.
[3]Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children[J]. Eur Respir J, 2020, 55(1): 1901136. DOI: 10.1183/13993003.01136-2019.
[4]游伟玲,李晓珍,张锋,等.中西医结合治疗咳嗽变异性哮喘临床观察[J].新中医,2017,49(6):40-42. DOI:10.13457/j.cnki.jncm.2017.06.013.
[5]李珊珊,张云沛,刘晓锡.加味麻杏石甘汤联合阿奇霉素序贯疗法治疗小儿支原体肺炎患儿的疗效及对血清炎症因子、氧化应激反应的影响[J].临床和实验医学杂志,2023,22(8):870-875. DOI:10.3969/j.issn.1671-4695.2023.08.023.
[6]刘博,张婷婷,邹雪,等.小柴胡汤加陈皮治疗咳嗽变异性哮喘[J].吉林中医药,2025,45(1):69-71.DOI:10.13463/j.cnki.jlzyy.2025.01.017.
[7]中华医学会儿科学分会呼吸学组慢性咳嗽协作组,«中华儿科杂志»编辑委员会.中国儿童慢性咳嗽诊断与治疗指南(2013年修订)[J].中华儿科杂志,2014,52(3):184-188. DOI:10.3760/cma.j.issn.0578-1310.2014.03.005.
[8]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002: 60-66.
[9]肖愉箫,张亚杰,王星.三拗汤对咳嗽变异性哮喘小鼠Th17/Treg免疫平衡的影响[J].中成药,2023,45(4):1300-1304.DOI:10.3969/j.issn.1001-1528.2023.04.046.
[10]Yi F, Jiang Z, Li H, et al. Small airway dysfunction in cough variant asthma: prevalence, clinical, and pathophysiological features[J]. Front Physiol, 2022, 12: 761622. DOI: 10.3389/fphys.2021.761622.
[11]Niimi A. Narrative review: how long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated?[J]. J Thorac Dis, 2021, 13(5): 3197-3214. DOI: 10.21037/jtd-20-2026.
[12]晁婵.胸腺基质淋巴细胞生成素联合小气道肺功能指标诊断儿童咳嗽变异性哮喘的临床价值[J].中国免疫学杂志,2023,39(7):1490-1493.DOI:10.3969/j.issn.1000-484X.2023.07.027.
[13]张志杰,黄贵锐,张诗瑜,等.5种经典名方治疗儿童咳嗽变异性哮喘的网状Meta分析[J].世界中医药,2023,18(16):2328-2335.DOI:10.3969/j.issn.1673-7202.2023.16.011.
[14]陈秋玲,周蓓,李燕玲,等.甘草次酸对咳嗽变异性哮喘小鼠Th1/Th2平衡影响的研究[J].海南医学院学报,2023,29(16):1201-1206. DOI:10.13210/j.cnki.jhmu.20230703.001.
[15]荆瑶瑶,邢龄艺,李想,等.麻杏石甘汤现代研究概述[J].天津中医药大学学报,2023,42(2):264-272. DOI:10.11656/j.issn.1673-9043.2023.02.22.
[16]苏文俊,高峰.皮下免疫治疗对变应性鼻炎伴咳嗽变异性哮喘患儿CD14、可溶性程序性细胞死亡配体1、特异性免疫球蛋白G4及炎症因子的影响[J].中国耳鼻咽喉头颈外科,2023,30(2):93-97. DOI:10.16066/j.1672-7002.2023.02.006.
[17]王军,张东,冯贞贞,等.咳嗽变异性哮喘常见证候研究[J].中国全科医学,2023,26(3):321-328,334. DOI:10.12114/j.issn.1007-9572.2022.0287.
[18]乔阳至子,杨道文.基于网络药理学及分子对接探讨益气疏风降肺方治疗咳嗽变异性哮喘的作用机制[J].中国中医基础医学杂志,2023,29(8):1358-1364. DOI:10.19945/j.cnki.issn.1006-3250.20230519.001.
[19]熊坚,黄慧,张颖春,等.基于R语言数据挖掘技术分析针灸治疗咳嗽变异性哮喘的取穴规律[J].护理研究,2023,37(4):671-677. DOI:10.12102/j.issn.1009-6493.2023.04.021.
[20]仇志锴,王春莲,尤士军,等.麻杏石甘汤合过敏煎加味对咳嗽变异性哮喘患儿症状改善及诱导痰炎性因子的影响[J].中国实验方剂学杂志,2023,29(8):214-219.DOI:10.13422/j.cnki.syfjx.202202226.
[21]王亚红.麻杏石甘汤化裁辨治小儿痰热型咳嗽变异性哮喘疗效观察[J].新中医,2015,47(4):196-197. DOI:10.13457/j.cnki.jncm.2015.04.094.
[22]文丹丹,王敏.麻杏石甘汤治疗咳嗽变异性哮喘的研究进展[J].中国实验方剂学杂志,2012,18(8):285-287. DOI:10.3969/j.issn.1005-9903.2012.08.084.
[23]王思源,韩波,南春红,等.麻杏石甘汤对RSV诱导哮喘小鼠肺组织炎症反应的影响及机制[J].山东医药,2020,60(1):48-51. DOI:10.3969/j.issn.1002-266X.2020.01.012.
[24]梁文能,丘振文,王沛坚.麻杏石甘汤治疗支气管哮喘的药效学研究[J].时珍国医国药,2007,18(8):1949-1950. DOI:10.3969/j.issn.1008-0805.2007.08.080.
[25]韩凤芹,孙雪文,张新国,等.麻杏石甘汤对哮喘模型小鼠支气管黏膜和肺组织免疫的影响[J].时珍国医国药,2012,23(6):1398-1399. DOI:10.3969/j.issn.1008-0805.2012.06.035.
[26]李红,陈常青,李艳英,等.疏风止咳汤联合糖皮质激素治疗咳嗽变异性哮喘疗效研究[J].陕西中医,2023,44(3):312-315. DOI:10.3969/j.issn.1000-7369.2023.03.009.
[27]温柠如,黄赫,张雅凤.不同配伍比例的麻杏石甘汤治疗支气管哮喘急性发作期疗效观察[J].中华中医药学刊,2016,34(2):444-447. DOI:10.13193/j.issn.1673-7717.2016.02.056.
[28]Xu Q, Lu T, Song Z, et al. Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: a systematic review and meta-analysis[J]. Clin Respir J, 2023, 17(10): 986-997. DOI: 10.1111/crj.13629.
[29]Chen YB, Shergis JL, Wu ZH, et al. Herbal medicine for adult patients with cough variant asthma: a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med, 2021, 2021: 5853137. DOI: 10.1155/2021/5853137.
[30]Nguyen V, Zhang Q, Pan F, et al. Zi-Su-Zi decoction improves airway hyperresponsiveness in cough-variant asthma rat model through PI3K/AKT1/mTOR, JAK2/STAT3 and HIF-1α/NF-κB signaling pathways[J]. J Ethnopharmacol, 2023, 314: 116637. DOI: 10.1016/j.jep.2023.116637.
|